

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number
WO 02/02112 A1

(51) International Patent Classification⁷: **A61K 31/4196**,
31/167, 31/4166, 31/57, A61P 5/28, 35/00

(21) International Application Number: PCT/SE01/01546

(22) International Filing Date: 4 July 2001 (04.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0016427.7 5 July 2000 (05.07.2000) GB
0020769.6 24 August 2000 (24.08.2000) GB

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COCKSHOT, Ian** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TF (GB). **FURR, Barrington** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMBINATION OF AN ANTI-ANDROGEN AND ANASTROZOLE FOR PROVIDING AN ANTIANDROGENIC EFFECT AND AROMATASE INHIBITION

(57) Abstract: The present invention relates to a pharmaceutical product, daily dose or dose regimen comprising an anti-androgen and anastrozole, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to a method of providing an anti-androgenic effect and aromatase inhibition in a patient, wherein the aromatase inhibition is provided substantially without causing an additional increase in the levels of circulating androgens.

WO 02/02112 A1

Pharmaceutical combination of an anti-androgen and anastrozole for providing an anti-androgenic effect and aromatase inhibition


PHARMACEUTICAL COMBINATION

The present invention relates to a pharmaceutical product, daily dose or dose regimen comprising an anti-androgen and anastrozole, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone. The invention also relates to a method of providing an anti-androgenic effect and aromatase inhibition in a patient, wherein the aromatase inhibition is provided substantially without causing an additional increase in the levels of circulating androgens. Furthermore, the invention relates to the use of an anti-androgen and anastrozole in the manufacture of a pharmaceutical product for this purpose, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone.


BACKGROUND TO THE INVENTION

15

Anastrozole, an aromatase inhibitor, is known by the AstraZeneca trade name ARIMIDEXTM. Anastrozole is known as 2,2'-[5-(1*H*-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methyl-propionitrile), which is disclosed in US re-issue No. 36,617. An alternative name is 2,2'-dimethyl-2,2'-[5-(1*H*-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(propiononitrile). The corresponding structure is shown in formula I:-




Flutamide, an anti-androgen, is known by the trade name EULEXINTM. Flutamide is also known by the alternative names 2-methyl-*N*-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; α,α,α -trifluoro-2-methyl-4'-nitro-*m*-propionotoluidide; and 4'-nitro-3'-trifluoromethylisobutyranilide. Flutamide is disclosed in US 3,847,988. The corresponding structure is shown in formula II:-



II

Nilutamide, an anti-androgen, is known by the trade name NILANDRONTM. Nilutamide is also known by the alternative names 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; and 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-2,5-dione. Nilutamide is disclosed in US 4,097,578. The corresponding structure is shown in formula III:-



III

Chlormadinone, in its acetate form, is an anti-androgen. The acetate form is known by the alternative names 17-(acetyloxy)-6-chloropregna-4,6-diene-3,20-dione; 6-chloro-17-hydroxypregna-4,6-diene-3,20-dione acetate; 6-chloro-6-dehydro-17 α -hydroxyprogesterone acetate; 6-chloro-6-dehydro-17 α -acetoxyprogesterone; and 17 α -acetox-6-choro-6,7-dehydroprogesterone. Chormadinone is disclosed in US 3,485,852.

Cyproterone is known by the alternative names (1 β ,2 β)-6-chloro-1,2-dihydro-17-hydroxy-3'*H*-cyclopropa[1,2]pregna-1,4,6-triene-3,20 dione; 6-chloro-17-hydroxy-1 α ,2 α -methylenepregna-4,6-diene-3,20-dione; 6-chloro-6-dehydro-17 α -hydroxy-1,2 α -methyleneprogesterone; and 6-chloro-1,2 α -methylene-4,6-pregnadien-17 α -ol-3,20-dione. Cyproterone is disclosed in US 3,234,093. Cyproterone in its free alcohol and acetate forms is an anti-androgen.

Anti-androgens such as flutamide and nilutamide are used in the treatment of prostate cancer. This is also the case for another anti-androgen, bicalutamide. Such compounds are generally used in combination with an inhibitor of gonadotrophin secretion, for example a luteinising hormone releasing hormone (LHRH) agonist such as goserelin, buserelin, leuprorelin or triptorelin. The properties and usefulness of these anti-androgens have been reviewed, for example in the following documents which are incorporated herein by way of reference :-

- | | |
|--------------|--|
| flutamide | R O Neri, <u>J. Drug Develop.</u> , 1987, <u>1</u> (Suppl.), 5-9 and <u>Urology</u> , 1989, <u>34</u> (Suppl. 4), 19-21 and United Kingdom Patent Application No. 1360001; |
| bicalutamide | B J A Furr <i>et al.</i> , <u>Urology</u> , 1996, <u>47</u> (Suppl. 1A), 13-25,
G J C Kolvenbag <i>et al.</i> , <u>Urology</u> , 1996, <u>47</u> (Suppl. 1A), 70-79 and
European Patent Application No. 0100172 as the 8th compound listed
in the table in Example 6; |
| nilutamide | M G Harris <i>et al.</i> , <u>Drugs and Aging</u> , 1993, <u>3</u> , 9-25 and United
Kingdom Patent Application No.1518444. |

It has been observed that administration of flutamide, bicalutamide or nilutamide in single agent therapy to humans causes an increase in the amount of testosterone circulating in the blood. For example, it has been disclosed that administration of bicalutamide leads to an approximate doubling of the basal level of circulating testosterone (G R P Blackledge *et al.*, Urology, 1996, 47 (Suppl. 1A), 44-47). Likewise, it has been disclosed that administration of flutamide causes a 50 to 80% increase in the basal level of circulating testosterone (L Boccon-Gibod *et al.*, J. Urology, 1992, 147, 417A, Abstract 818 and European Urology, 1997, 32, 391-395 and Brufsky *et al.*, Urology, 1997, 49, 913-920). Likewise, administration of nilutamide causes an increase in the basal level of circulating testosterone (A U Decensi *et al.*, J. Urology, 1991, 146, 377-381). It is believed that such increases in the level of testosterone occur when sufficient of the anti-androgen gains access to the CNS and blocks androgen receptors in the hypothalamus. The consequential lack of feedback of androgen causes additional release of LHRH by the hypothalamus which in turn causes release of luteinising hormone (LH) and follicle stimulating hormone (FSH) by the pituitary gland and production of testosterone in the testes. Aromatase enzyme in fat and other tissues converts some of the increased concentration of testosterone to oestradiol, which results in increased concentrations of oestrogen in the blood. Further discussion of this is provided by C Mahler *et al.*, Clinical Pharmacokinetics, 1998, 34(5), pp 405-417.

A disadvantageous effect is produced. Namely, the increase in the levels of circulating oestrogen may cause one or more of the side effects of gynaecomastia, breast tenderness, hot flushes, impotence and reduction in libido. A discussion on gynaecomastia can be found in C J Tyrrell, Prostate Cancer and Prostatic Diseases, 1999, 2(4): pp 167-171.

As explained above, the testosterone and LH levels tend to rise. Mahler *et al.* explain that the rising oestrogen levels progressively activate the normal feedback mechanism, and so the rise in LH and testosterone is limited. It is widely accepted in the art that oestrogen levels are important in regulating LH secretion, and by this means testosterone secretion, as invoked by Mahler *et al.* It is clear from numerous publications that the reduction of the negative feedback effect of oestrogens on the hypothalamic-pituitary axis in men and male animals results in an increase in luteinising hormone (LH) secretion. This in turn drives

the testes to produce increased quantities of testosterone. In this respect, reference is made to F H Comhaire *et al*, Human Reproduction, 1995, 10 (7), pp 1740-1744, where tamoxifen (an anti-oestrogen) intake in adult men was reported to increase testosterone and LH.

5

JJ Spijkstra *et al*, J. Clinical Endocrinology and Metabolism, 1988, 66(2), pp 355-360, reports a study of LH secretion in 13 normal men before and after the administration of tamoxifen for a 6 week period. An increase in mean serum testosterone, oestradiol, LH levels, LH pulse frequency and LH pulse amplitude were observed after tamoxifen administration. Similar results were cited in men given the anti-oestrogen clomiphene citrate. Spijkstra *et al* suggest that the observed result with tamoxifen was due to an inhibition of negative feedback on pituitary oestrogen receptors.

DI Lewis-Jones *et al*, Andrologia 1987, 19(1): pp 86-90 reports that tamoxifen administration to men elevates the basal serum levels of LH, oestradiol "and particularly testosterone...The marked elevation in serum testosterone levels produced by the administration of tamoxifen may be a more successful method for elevating male hormone levels than the use of other pharmacological agents such as mesterolone".

L van Bergeijk *et al*, Horm. Metabol. Res., 1986, pp 558-564, reports that three months' treatment with tamoxifen in normogonadotrophic oligozoospermic men stimulated basal LH, FSH and testosterone levels. They suggested that oestrogens play a role in the negative feedback regulation of gonadotrophin release.

There is, therefore, comprehensive evidence that would lead the skilled person in the art to reject the idea of using an anti-oestrogen to combat the rise in oestrogen levels and associated side effects observed when an anti-androgen is administered to a male. This is because the anti-oestrogen would be expected, in view of the numerous previously reported studies, to interfere with the negative feedback effect of oestrogen at the hypothalamic-pituitary axis and thus produce a substantial additional increase in LH and

30

testosterone, which in turn would be expected to compromise the anti-androgenic effect of the anti-androgen. Furthermore, it follows from this that the skilled person would believe that the interference of this negative feedback by the use of an aromatase inhibitor would also produce a substantial additional increase in LH and testosterone, which in turn would be expected to compromise the anti-androgenic effect of the anti-androgen. There is therefore also a prejudice in the art against using an aromatase inhibitor to combat the rise in oestrogen levels and associated side effects observed when an anti-androgen is administered to a male. In addition, the skilled person would also predict that there would be an increase in testosterone due to the inhibition of its conversion to oestrogens, which would also lead the skilled person to reject the use of an aromatase inhibitor.

There is therefore a need for a treatment that can provide an anti-androgenic effect and combat the rise in oestrogen levels, thereby suppressing a side effect selected from gynaecomastia, breast tenderness, hot flushes, impotence and reduction in libido, without substantially causing an additional increase in the levels of circulating androgens above the levels produced by the anti-androgen alone.

SUMMARY OF THE INVENTION

The present invention fulfils this need by providing a pharmaceutical product for administration to a patient for providing an anti-androgenic effect and aromatase inhibition in the patient, the product comprising an anti-androgen and anastrozole or a pharmaceutically acceptable salt or solvate thereof, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof. The cyproterone is in its free alcohol or acetate form. Preferably, the anti-androgen and anastrozole are provided in a ratio of 25 to 1000 : 0.005 to 100 respectively.

As a result of the present invention, the aromatase inhibition is provided substantially without causing an additional increase in the levels of circulating androgens. By this, we mean that the androgen levels (eg, as indicated by total or free testosterone in blood) in the patient do not substantially increase above the level usually observed when the anti-
5 androgen alone is administered to patients.

The present invention also provides a daily pharmaceutical dose for administration to a patient for providing an anti-androgenic effect and aromatase inhibition in the patient, the dose comprising an anti-androgen and from 0.005 to 100 mg of anastrozole or a
10 pharmaceutically acceptable salt or solvate thereof, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.

In addition, the present invention provides a dose regimen for such purpose comprising an
15 anti-androgen and from 0.005 to 100 mg of anastrozole or a pharmaceutically acceptable salt or solvate thereof for simultaneous or sequential administration to the patient, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.

20 Other aspects of the invention relate to the use in the manufacture of a pharmaceutical product of an anti-androgen and anastrozole or a pharmaceutically acceptable salt or solvate thereof that are simultaneously or sequentially administrable to a patient, for:-

(a) providing an anti-androgenic effect and aromatase inhibition in the patient,
25 wherein the aromatase inhibition is provided substantially without causing an additional increase in the levels of circulating androgens; or

(b) providing an anti-androgenic effect in the patient and suppressing increase in the incidence or severity of a side effect selected from gynaecomastia, breast tenderness,

hot flushes, impotence and reduction in libido, substantially without causing an additional increase in the levels of circulating androgens;

wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.

By "suppressing increase in the incidence or severity of a side effect", we mean providing a lower incidence or severity compared with the side effect produced when the anti-androgen is administered alone, or eliminating the side effect.

The present invention further provides a method of providing an anti-androgenic effect in a patient comprising simultaneously or sequentially administering an anti-androgen and anastrozole or a pharmaceutically acceptable salt or solvate thereof to the patient, wherein the method further provides aromatase inhibition in the patient substantially without causing an additional increase in the levels of circulating androgens, and wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides both an anti-androgenic effect and aromatase inhibition in a patient, wherein the aromatase inhibition is produced substantially without causing an additional increase in the levels of circulating androgens. This is achieved by administering to the patient a product comprising an anti-androgen and anastrozole or a pharmaceutically acceptable salt or solvate thereof, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof. Preferably, the anti-androgen and anastrozole are provided in a ratio respectively of 25 to 1000 (preferably the lower end of the range being 50 or 100; preferably the upper end of the range being 500, 350, 300, 150 or 50; suitable

values in the ranges being 750, 375, 150, 125 or 50) : 0.005 to 100 (preferably the lower end of the range being 0.05 or 0.5; preferably the upper end of the range being 50, 10 or 1; the most preferred range being 0.5 to 1; a suitable value in the range being 1). For flutamide, a preferred range is 100 to 1000, and 750 or 375 is a preferred value. For
5 chlormadinone acetate a preferred value is 50. For cyproterone a preferred range is 200 to 300. For nilutamide, a preferred range is 50 to 500, and 300 or 150 is a preferred value. The term "product" is intended to mean either a mixture of the anti-androgen and anastrozole (eg, provided as a capsule or tablet containing both compounds) or a kit comprising separate amounts of the compounds (eg, a set of anastrozole tablets and a
10 separate set of tablets of the anti-androgen). The latter product can be used for simultaneous or sequential (ie, temporally spaced) administration of the compounds to the patient, while the pre-mixed compounds are for simultaneous administration. Factors such as the rate of absorption, metabolism and the rate of excretion of each agent will affect their presence at the tumour site. Such factors are routinely considered by, and are well
15 within the ordinary skill of, the clinician when he contemplates the treatment of a medical condition which requires the conjoint administration of two agents in order to obtain a beneficial effect.

The invention contemplates the use of pharmaceutically acceptable salts and solvates of the
20 anti-androgen (for flutamide and nilutamide) and/or anastrozole. Suitable salts are, for example acid addition salts, such as hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartarate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate, or alkali metal salts such as sodium or potassium salts.

25 The anastrozole is included to provide aromatase inhibition, in that this compound inhibits conversion of testosterone to oestradiol by aromatase enzyme.

The anti-androgenic effect is useful for treating cancer, for example prostate cancer. Particular examples are advanced prostate cancer and early prostate cancer. The anti-
30 androgenic effect may be useful for prophylaxis, in order to reduce the risk of prostate cancer occurrence in patients. This could be especially useful in men genetically pre-disposed to prostate cancer. Conventional methods are available to classify patients

according to their risk of contracting prostate cancer, for example by assessment of family history and measurements over time of particular blood proteins such as prostate specific antigen (PSA). Other uses for the anti-androgenic effect are the treatment of a non-malignant disease of the prostate gland (eg, benign prostatic hyperplasia or hypertrophy) and acne.

The aromatase inhibition is useful for suppressing increase in the incidence or severity of a side effect selected from gynaecomastia, breast tenderness, hot flushes, impotence, reduction in libido, nausea, vomiting, fatigue and diarrhoea. Such side effects have been observed with monotherapy use of anti-androgens. Preferably, the side effect is one or both of gynaecomastia and breast tenderness.

A suitable dose regimen or daily pharmaceutical dose comprises the anti-androgen and from 0.005 to 100 mg of anastrozole or a pharmaceutically acceptable salt or solvate thereof. Preferably, for the amount of anastrozole the lower end of the range is 0.05 or 0.5 mg; preferably the upper end of the range is 50, 10 or 1 mg; the most preferred range is 0.5 to 1 mg; a suitable value in the range being 1 mg. The dose or the regimen preferably comprises from 25 to 1000 mg of the anti-androgen or a pharmaceutically acceptable salt or solvate thereof. Preferably the lower end of the range is 50 or 100 mg; preferably the upper end of the range is 350, 300, 150 or 50 mg; suitable values in the ranges are 750, 375, 150, 125 or 50 mg. For flutamide, a preferred range is 100 to 1000 mg, and 750 or 375 mg is a preferred value. For chlormadinone acetate a preferred value is 50 mg. For cyproterone a preferred range is 200 to 300 mg. For nilutamide, a preferred range is 50 to 500 mg, and 300 or 150 mg is a preferred value.

For the regimen, each compound is preferably administered daily. Another possible regime would be dosing of the anti-androgen on alternate days and dosing of the anastrozole also on (the same or different) alternate days. To this end, the regimen may include administration instructions. Alternatively, a dose of the anti-androgen is administered every 3, 4, 5, 6 or 7 days and the anastrozole is administered every 3, 4, 5, 6

or 7 days (eg, on the same day as the anti-androgen).

In one embodiment, the regimen or daily dose comprises 3 times 250 mg of flutamide (eg, 250 mg administered every 8 hours) or 3 times 125 mg of flutamide (eg, 125 mg
5 administered every 8 hours).

The patient can be a human male, eg an adult, but the treatment of other mammals (except rats) is also contemplated.

10 The products, doses and regimens of the invention may be in a form suitable for oral use (for example as tablets, capsules, aqueous or oily suspensions, emulsions or dispersible powders or granules), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions; for example for use within a transdermal patch), for
parenteral administration (for example as a sterile aqueous or oily solution or suspension
15 for intravenous, subcutaneous, intramuscular or intravascular dosing), or as a suppository for rectal dosing. Preferably the compositions of the invention are in a form suitable for oral use, for example as tablets or capsules.

The products, doses and regimens of the invention may be obtained by conventional
20 procedures using conventional pharmaceutically-acceptable diluents or carriers that are well known in the art.

Suitable pharmaceutically-acceptable diluents or carriers for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or
25 calcium carbonate, granulating and disintegrating agents such as corn starch or alginic acid; binding agents such as gelatin or starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl
p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be
uncoated or coated either to modify their disintegration and the subsequent absorption of
30 the active ingredient within the gastrointestinal tract, or to improve their stability and/or

appearance, in either case using conventional coating agents and procedures well known in the art.

5 Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

10 When we mention providing aromatase inhibition without causing an additional increase in the levels of circulating androgens, we mean that the androgen levels (eg, as indicated by total or free testosterone in blood) in the patient do not substantially increase above the maximum level usually observed when the anti-androgen alone is administered to patients. An enabling illustration is provided in the human clinical trial below. While this relates to the use of ARIMIDEXTM (anastrozole) in combination with CASODEXTM (bicalutamide),
15 it is expected that the use of a combination according to the present invention in a similar trial also demonstrates the effect.

HUMAN CLINICAL TRIAL

20

The following clinical trial was performed to determine the effect of the administration of CASODEXTM together with ARIMIDEXTM on free testosterone levels in healthy male volunteers over a 6 week period.

Protocol

25

Key Inclusion Criteria: Male, aged 65 years or above showing no clinically significant abnormalities in routine haematological and biochemical tests and having endocrinology and prostate specific antigen (PSA) results within normal limits.

30

Key Exclusion Criteria: Previous inclusion in a clinical trial using CASODEX™; concurrent treatment with any drugs with the exception of paracetamol; history or presence of any testicular abnormality; history or presence of gastrointestinal, hepatic or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs; a clinically significant illness within 2 weeks of trial commencement; definite or suspected personal or family history of significant adverse drug reactions or any hypersensitivity to CASODEX™ or ARIMIDEX™; treatment within the previous 3 months with any drugs known to have a well-defined potential for hepatotoxicity or hepatic interaction.

Dosage: The CASODEX™ was administered daily at a dose of 150 mg and the ARIMIDEX™ was administered daily at a dose of 1 mg. All treatments were in tablet form and taken once daily. Daily treatment with CASODEX™ was for 6 weeks, and with ARIMIDEX™ for the final 2 weeks of this period. The treatment periods were selected as the minimum time to attain steady-state plasma concentrations for the drugs.

Key Assessment: Free testosterone concentrations were measured during the course of the trial.

Results

A summary of the free testosterone concentrations over the treatment periods is presented in Table 1.

Table 1 Free testosterone concentrations following treatment with CASODEX™ alone (up to week 4) plus ARIMIDEX™ (after week 4)

Parameter	Day 1	Day 29	Day 36	Day 43	Follow-up
Testosterone (nmol/l)					
n	7	7	7	7	7

gmean	0.048	0.076	0.075	0.074	0.049
CV	30.415	26.219	45.199	46.883	36.081
Minimum	0.03 - 0.07	0.00 - 0.12	0.03 - 0.11	0.03 - 0.13	0.03 - 0.09
Ratio to Day 1	-	1.58	1.56	1.54	1.01

CV=Coefficient of variation gmean=Geometric mean n=Number of observations

Day 1 samples were drawn before dosing, and therefore act as a baseline measurement.

- 5 No volunteers experienced gynaecomastia.

Conclusion

When CASODEXTM alone was administered, the mean free testosterone concentration
 10 increased 58% by the end of the treatment period. With continued administration of
 CASODEXTM beyond the 4th week, this figure would be expected to rise (corresponding to
 an approximate doubling of the mean total testosterone concentration). In this respect,
 reference is made to a trial reported by Verhelst, J *et al* ("Endocrine profiles during
 administration of the new non-steroidal anti-androgen Casodex in prostate cancer",
 15 Verhelst, J *et al*, Clin. Endocrinol. (Oxf) 1994, Oct., 41(4), pp 525-30), which reported an
 increase of 57% in the mean free testosterone concentration after 24 weeks of daily
 administration of 150 mg CASODEXTM alone.

Reference to Table 1 shows that the co-administration of ARIMIDEXTM with CASODEXTM
 20 produced no additional clinically significant change in the mean concentration of free
 testosterone. By the end of the treatment period the increase in the mean concentration
 was 54%.

The results therefore support the present invention wherein the anastrozole does not
 25 compromise the anti-androgenic effect, in that contrary to the expectations of the skilled
 person based on the aforementioned prejudice in the art, the anastrozole does not cause an

additional increase in the levels of androgens beyond the levels expected when anti-androgen alone is used.

CLAIMS

1. A pharmaceutical product for administration to a patient for providing an anti-androgenic effect and aromatase inhibition in the patient, the product comprising an anti-androgen and anastrozole or a pharmaceutically acceptable salt or solvate thereof,
5 wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.
2. The pharmaceutical product of claim 1, wherein the anti-androgen and anastrozole are
10 provided in a ratio of 25 to 1000 : 0.005 to 100 respectively.
3. A daily pharmaceutical dose for administration to a patient for providing an anti-androgenic effect and aromatase inhibition in the patient, the dose comprising an anti-androgen and from 0.005 to 100 mg of anastrozole or a pharmaceutically acceptable
15 salt or solvate thereof, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.
4. A dose regimen for providing an anti-androgenic effect and aromatase inhibition in a
20 patient, the regimen comprising an anti-androgen and from 0.005 to 100 mg of anastrozole or a pharmaceutically acceptable salt or solvate thereof for simultaneous or sequential administration to the patient, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.
- 25 5. The dose of claim 3, or the regimen of claim 4, comprising from 25 to 1000 mg of the anti-androgen.
6. Use in the manufacture of a pharmaceutical product of an anti-androgen and
30 anastrozole or a pharmaceutically acceptable salt or solvate thereof for simultaneous or

sequential administration to a patient, for providing an anti-androgenic effect and aromatase inhibition in the patient, wherein the aromatase inhibition is provided substantially without causing an additional increase in the levels of circulating androgens, and wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.

7. Use in the manufacture of a pharmaceutical product of an anti-androgen and anastrozole or a pharmaceutically acceptable salt or solvate thereof for simultaneous or sequential administration to a patient, for providing an anti-androgenic effect in the patient and suppressing increase in the incidence or severity of at least one side effect selected from gynaecomastia, breast tenderness, hot flushes, impotence and reduction in libido, substantially without causing an additional increase in the levels of circulating androgens, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.
8. A method of providing an anti-androgenic effect in a patient comprising simultaneously or sequentially administering an anti-androgen and anastrozole or a pharmaceutically acceptable salt or solvate thereof to the patient, wherein the method further provides aromatase inhibition in the patient substantially without causing an additional increase in the levels of circulating androgens, and wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or a pharmaceutically acceptable salt or solvate thereof.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01546

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/4196, A61K 31/167, A61K 31/4166, A61K 31/57, A61P 5/28, A61P 35/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,X	WO 0149294 A1 (PHARMACIA & UPJOHN S.P.A.), 12 July 2001 (12.07.01) --	1-8
X	US 4895715 A (RUDOLPH NERI ET AL), 23 January 1990 (23.01.90), the abstract; column 3, line 12 - column 4, line 40; the claims --	1-8
X	GB 2102287 A (SCHERING AG), 2 February 1983 (02.02.83), page 2, line 4 -line 39; claims 28, 29 --	1-8
A	Endocrine-Related Cancer, Volume 6, 1999, R C Coombes et al, "Aromatase inhibitors and their use in the sequential setting" page 259 - page 263 --	1-8

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 2001

Date of mailing of the international search report

16 -10- 2001

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/Eö
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01546

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9803180 A2 (THE VICTORIA UNIVERSITY OF MANCHESTER), 29 January 1998 (29.01.98), page 12, second paragraph - third paragraph; page 13, second paragraph; claims 1, 14, 18, 21-24 --	1-8
A	Urology, Volume 54, No 6A, 1999, Jerome P. Richie, "Anti-androgens and other hormonal therapies for prostate cancer" page 15 - page 18 -- -----	1-8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE01/01546**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **3-8**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE01/01546

With the present wording claims 3-8 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT
Information on patent family members

01/10/01

International application No.
PCT/SE 01/01546

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0149294	A1	12/07/01	GB	9930839 D	00/00/00
US	4895715	A	23/01/90	NONE		
GB	2102287	A	02/02/83	AU	563785 B	23/07/87
				AU	8407582 A	25/11/82
				BE	890522 A	29/03/82
				CA	1186998 A	14/05/85
				CH	648211 A	15/03/85
				DE	3121152 A,C	09/12/82
				DK	354881 A	23/11/82
				FR	2506158 A,B	26/11/82
				IE	53394 B	09/11/88
				IT	1139175 B	24/09/86
				IT	8123988 D	00/00/00
				JP	1050207 B	27/10/89
				JP	57193412 A	27/11/82
				LU	83545 A	01/12/81
				NL	8103875 A	16/12/82
				SE	463074 B,C	08/10/90
				SE	8104624 A	23/11/82
				US	4598072 A	01/07/86
				ZA	8203501 A	30/03/83
WO	9803180	A2	29/01/98	AU	734465 B	14/06/01
				AU	3628897 A	10/02/98
				CA	2261263 A	29/01/98
				EP	0930876 A	28/07/99
				GB	9615348 D	00/00/00
				JP	2000515523 T	21/11/00
				ZA	9706480 A	22/01/99
				AU	723787 B	07/09/00
				AU	3100097 A	07/01/98
				DE	19781815 T	17/06/99
				GB	2330111 A,B	14/04/99
				GB	9701600 D	00/00/00
				GB	9826788 D	00/00/00
				US	6089614 A	18/07/00

THIS PAGE BLANK (USPTO)